Loading…
Chinese contract research organization providing preclinical safety and toxicology testing for drug developers.
Chinese contract research organization providing preclinical safety and toxicology testing for drug developers.
Charges a fee per study run on a drug developer's behalf, such as safety and toxicology tests in animals, so income follows how many drug programmes its clients start and how well biotech funding holds up. Supply from its own primate colony helps secure capacity for the tests that need it.
In one line: A Chinese Charles River Laboratories.
Moat: narrow (scale, regulatory licence, installed base). Large non-human-primate colony and GLP-certified labs are costly and slow for rivals to replicate.
Headquarters: Beijing, China · Employees: 2,649
Size Joinn Laboratories (China) (603127.SS) is a China Health Care company (Biotechnology) with a market value of $4.58B, the 554th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥44.55 on 6 Nov 2026.
Performance Over six months the shares gained 14.6%, against -2.3% for the median peer and -16.4% for the China market (cap-weighted) — 9th highest of 21 in its peer set.
Growth Revenue grew 11.5% over the last twelve months (peer median +8.3%); the operating margin is -3.8% (peer median -35.0%).
Valuation It trades at 40.9× forward earnings against a peer median of 31.9× (3rd most expensive of 7).
Capital Return on invested capital runs 10.6 points below its cost of capital (11.1% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥1.86B | CN¥1.66B | CN¥2.02B | CN¥2.38B | CN¥2.26B |
| Revenue growth | — | -18% | -15% | +6% | — |
| Gross profit | CN¥546M | CN¥302M | CN¥532M | CN¥986M | CN¥1.04B |
| EBITDA | n/a | CN¥33.9M | CN¥218M | CN¥718M | CN¥824M |
| Net income | CN¥1.15B | CN¥298M | CN¥74.1M | CN¥397M | CN¥1.07B |
| Free cash flow | CN¥649M | CN¥376M | CN¥264M | CN¥455M | CN¥738M |
| Capital expenditure | CN¥453M | CN¥144M | CN¥269M | CN¥193M | CN¥275M |
| Total debt | CN¥37.1M | CN¥21.6M | CN¥61.0M | CN¥85.8M | CN¥120M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Joinn Laboratories (China) 603127.SS | $4.58B | +15% | +12% | -4% | 40.9× | n/a |
| Charles River Laboratories CRL | $16.1B | +90% | -1% | 15% | 26.6× | 25.3% |
| Wuxi Apptec 2359.HK | $66.3B | +40% | +38% | 44% | 20.4× | 8.7% |
| Pharmaron Beijing 3759.HK | $11.3B | +45% | +24% | 14% | 22.9× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 603127.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -14.4% | +3.8% | lowest of 21 |
| 6-month return | +14.6% | -2.3% | 9th highest of 21 |
| Distance from 52-week high | -20.0% | -24.0% | 7th highest of 21 |
| Revenue growth (TTM) | +11.5% | +8.3% | 8th highest of 16 |
| Operating margin | -3.8% | -35.0% | 7th highest of 16 |
| Forward P/E | 40.9× | 31.9× | 3rd most expensive of 7 |
| ROIC minus cost of capital | -10.6 pp | -11.2 pp | 7th highest of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Joinn Laboratories (China) 603127.SS | China | $4.58B | +15% | +12% | -4% | 40.9× | n/a | n/a |
| Changchun High-Tech Industry (Group) 000661.SZ | China | $4.51B | -13% | -18% | -1% | 30.2× | 32.2% | +7.1% |
| Adaptive Biotechnologies ADPT | United States | $4.47B | +103% | +50% | -12% | n/a | n/a | n/a |
| Beijing Wantai Biological Pharmacy Enterprise 603392.SS | China | $4.72B | -37% | +8% | -35% | n/a | n/a | n/a |
| Dianthus Therapeutics DNTH | United States | $4.81B | -1% | -61% | -11,441% | n/a | n/a | n/a |
| CRISPR Therapeutics CRSP | United States | $4.86B | -9% | -34% | -2,059% | n/a | n/a | n/a |
| Shanghai RAAS Blood Products 002252.SZ | China | $4.89B | -11% | -22% | 17% | 13.7× | n/a | n/a |
| Edgewise Therapeutics EWTX | United States | $4.89B | +28% | n/a | n/a | n/a | n/a | n/a |
| 3SBio 1530.HK | Hong Kong | $4.92B | -34% | +102% | 61% | 13.7× | n/a | n/a |
| Relay Therapeutics RLAY | United States | $4.08B | +46% | +24% | -2,999% | n/a | n/a | n/a |
| Chongqing Zhifei Biological Products 300122.SZ | China | $5.35B | -2% | -28% | -210% | n/a | -6.4% | -10.0% |
| AbCellera Biologics ABCL | United States | $3.85B | +149% | +101% | -340% | n/a | n/a | n/a |
| Anthem Biosciences ANTHEM.NS | India | $5.46B | +17% | -1% | 35% | 69.9× | 36.7% | +26.2% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 300347.SZ | China | $5.58B | -6% | +16% | 10% | 110.0× | 28.4% | +16.4% |
| Beijing Tiantan Biological Products 600161.SS | China | $3.76B | -11% | -13% | 21% | 33.6× | 3.2% | +12.5% |
| Lin BioScience 6696.TWO | Taiwan | $3.74B | +129% | n/a | n/a | n/a | n/a | n/a |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Iovance Biotherapeutics IOVA | United States | $3.64B | +64% | +35% | -91% | n/a | n/a | n/a |
| Tango Therapeutics TNGX | United States | $3.63B | -7% | +121% | -253% | n/a | n/a | n/a |
| Enliven Therapeutics ELVN | United States | $3.62B | +21% | n/a | n/a | n/a | n/a | n/a |